Gazdar AF, Bunn PA, Minna JD. Small-cell lung cancer: what we know, what we need to know and the path forward. Nat Rev Cancer. 2017;17:725–37.

Article  CAS  PubMed  Google Scholar 

Turrisi AT. 3rd: limited stage small cell lung cancer: treatment and therapy. Curr Treat Options Oncol. 2003;4:61–4.

Article  PubMed  Google Scholar 

Zugazagoitia J, Paz-Ares L. Extensive-Stage Small-Cell lung cancer: First-Line and Second-Line treatment options. J Clin Oncol. 2022;40:671–80.

Article  CAS  PubMed  Google Scholar 

Wakeam E, Acuna SA, Leighl NB, Giuliani ME, Finlayson SRG, Varghese TK, Darling GE. Surgery versus chemotherapy and radiotherapy for early and locally advanced small cell lung cancer: A Propensity-Matched analysis of survival. Lung Cancer. 2017;109:78–88.

Article  CAS  PubMed  Google Scholar 

Zhong L, Suo J, Wang Y, Han J, Zhou H, Wei H, Zhu J. Prognosis of limited-stage small cell lung cancer with comprehensive treatment including radical resection. World J Surg Oncol. 2020;18:27.

Article  PubMed  PubMed Central  Google Scholar 

Yang CJ, Chan DY, Speicher PJ, Gulack BC, Tong BC, Hartwig MG, Kelsey CR, D’Amico TA, Berry MF, Harpole DH. Surgery versus optimal medical management for N1 small cell lung cancer. Ann Thorac Surg. 2017;103:1767–72.

Article  PubMed  Google Scholar 

Liu T, Chen Z, Dang J, Li G. The role of surgery in stage I to III small cell lung cancer: a systematic review and meta-analysis. PLoS ONE. 2018;13:e0210001.

Article  PubMed  PubMed Central  Google Scholar 

Takenaka T, Takenoyama M, Inamasu E, Yoshida T, Toyokawa G, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Ichinose Y. Role of surgical resection for patients with limited disease-small cell lung cancer. Lung Cancer. 2015;88:52–6.

Article  PubMed  Google Scholar 

Yao Y, Zhou Y, Yang Z, Huang H, Shen H. Adjuvant chemotherapy following surgical resection improves survival in patients with early stage small cell lung cancer. Oncol Res. 2019;27:203–10.

Article  PubMed  PubMed Central  Google Scholar 

Zhou N, Bott M, Park BJ, Vallières E, Wilshire CL, Yasufuku K, Spicer JD, Jones DR, Sepesi B. Predictors of survival following surgical resection of limited-stage small cell lung cancer. J Thorac Cardiovasc Surg. 2021;161:760–e771762.

Article  PubMed  Google Scholar 

Li Y, Wang Y, Zhou W, Chen Y, Lou Y, Qian F, Lu J, Jiang H, Xiang B, Zhang Y, et al. Different clinical characteristics and survival between surgically resected pure and combined small cell lung cancer. Thorac Cancer. 2022;13:2711–22.

Article  PubMed  PubMed Central  Google Scholar 

Tian Y, Zhai X, Han A, Zhu H, Yu J. Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint Blockades in small cell lung cancer. J Hematol Oncol. 2019;12:67.

Article  PubMed  PubMed Central  Google Scholar 

Chan TA, Yarchoan M, Jaffee E, Swanton C, Quezada SA, Stenzinger A, Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30:44–56.

Article  CAS  PubMed  Google Scholar 

Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M et al. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018, 362.

McGranahan N, Furness AJ, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, Jamal-Hanjani M, Wilson GA, Birkbak NJ, Hiley CT, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint Blockade. Science. 2016;351:1463–9.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lu S, Stein JE, Rimm DL, Wang DW, Bell JM, Johnson DB, Sosman JA, Schalper KA, Anders RA, Wang H, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: a systematic review and meta-analysis. JAMA Oncol. 2019;5:1195–204.

Article  PubMed  PubMed Central  Google Scholar 

Zhang Z, Zhang C, Luo Y, Wu P, Zhang G, Zeng Q, Wang L, Yang Z, Xue L, Zheng B, et al. m(6)A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer. BMC Med. 2021;19:284.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li Y, Shi X, Mao B, Wang L, Wu L, Li J, Jiao S. The genomic mutational landscape and its correlation with TMB, PD-L1 expression and CD8(+) T cell infiltration in Chinese lung large cell neuroendocrine carcinoma. Lung Cancer. 2022;166:161–9.

Article  CAS  PubMed  Google Scholar 

Liu H, He W, Wang B, Xu K, Han J, Zheng J, Ren J, Shao L, Bo S, Lu S, et al. MALBAC-based chromosomal imbalance analysis: a novel technique enabling effective non-invasive diagnosis and monitoring of bladder cancer. BMC Cancer. 2018;18:659.

Article  PubMed  PubMed Central  Google Scholar 

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47–53.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li W, Ye L, Huang Y, Zhou F, Wu C, Wu F, He Y, Li X, Wang H, Xiong A, et al. Characteristics of Notch signaling pathway and its correlation with immune microenvironment in SCLC. Lung Cancer. 2022;167:25–33.

Article  PubMed  Google Scholar 

Lin A, Zhou N, Zhu W, Zhang J, Wei T, Guo L, Luo P, Zhang J. Genomic and immunological profiles of small-cell lung cancer between East Asians and Caucasian. Cancer Cell Int. 2022;22:173.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sutherland KD, Ireland AS, Oliver TG. Killing SCLC: insights into how to target a shapeshifting tumor. Genes Dev. 2022;36:241–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nguyen LT, Ohashi PS. Clinical Blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol. 2015;15:45–56.

Article  CAS  PubMed  Google Scholar 

Baessler A, Vignali DAA. T cell exhaustion. Annu Rev Immunol. 2024;42:179–206.

Article  CAS  PubMed  Google Scholar 

Zhang M, Li G, Wang Y, Wang Y, Zhao S, Haihong P, Zhao H, Wang Y. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017;7:10255.

Article  PubMed  PubMed Central  Google Scholar 

Toyokawa G, Takada K, Haratake N, Takamori S, Akamine T, Katsura M, Fujishita T, Shoji F, Okamoto T, Oda Y, Maehara Y. Favorable disease-free survival associated with programmed death ligand 1 expression in patients with surgically resected small-cell lung cancer. Anticancer Res. 2016;36:4329–36.

CAS  PubMed  Google Scholar 

Miao L, Lu Y, Xu Y, Zhang G, Huang Z, Gong L, Fan Y. PD-L1 and c-MET expression and survival in patients with small cell lung cancer. Oncotarget. 2017;8:53978–88.

Article  PubMed  PubMed Central  Google Scholar 

Ishii H, Azuma K, Kawahara A, Yamada K, Imamura Y, Tokito T, Kinoshita T, Kage M, Hoshino T. Significance of programmed cell death-ligand 1 expression and its association with survival in patients with small cell lung cancer. J Thorac Oncol. 2015;10:426–30.

Article  CAS  PubMed  Google Scholar 

Chang YL, Yang CY, Huang YL, Wu CT, Yang PC. High PD-L1 expression is associated with stage IV disease and poorer overall survival in 186 cases of small cell lung cancers. Oncotarget. 2017;8:18021–30.

Article  PubMed  PubMed Central  Google Scholar 

Zhao X, Kallakury B, Chahine JJ, Hartmann D, Zhang Y, Chen Y, Zhang H, Zhang B, Wang C, Giaccone G. Surgical resection of SCLC: prognostic factors and the tumor microenvironment. J Thorac Oncol. 2019;14:914–23.

Article